Delphi Diagnostics is developing next-generation diagnostics to personalize breast cancer treatment decisions. Utilizing the Endocrine Activity Index, Delphi Diagnostics is providing new …

The DELFI method analyzes fragments of cell-free DNA in a simple liquid biopsy blood sample using novel machine learning and next-generation sequencing to support early-stage cancer …

Delphi Diagnostics is focused on helping patients, providers and the healthcare system by providing next generation diagnostic tests to optimize breast cancer treatment decisions.

EAI is a gene expression profile test that measures endocrine activity in a tumor. What information will my test results provide? With the results from EAI Recurrence Risk, you and your doctor …

Delphi Diagnostics is providing the next generation of diagnostics to personalize breast cancer treatment decisions. Using the resources below, investors can learn more about our company …

Learn more about the various leadership team members behind Delphi Diagnostics, our Board of Directors, Executive Team, and Senior Advisors.

For breast oncologists, today’s diagnostic tests answer broad questions to inform breast cancer treatment decisions.

Dr. Symmans is the lead inventor of the intellectual property underlying Delphi’s product line. Dr. Symmans holds founder shares in Delphi Diagnostics Inc. His employment with MD Anderson …

Delphi’s latest hardware solutions, DS380E and DS580E, are designed to elevate your workshop’s diagnostic capabilities - whether you're servicing cars, LCVs, or heavy-duty.

Delphi Diagnostics provide delphi’s sensitivity to endocrine therapy. It is a gene expression interpretive algorithm that measures potential disease progression on endocrine therapy in …